Immune checkpoint inhibitors (ICIs), targeting either programmed death‐1 (PD1) or programmed death‐ligand‐1 (PD‐L1), have revolutionized treatment of some tumor types in adults, such as lung cancer and melanoma. Here, CD274 is linked to neoplasm.